Table 2.
Cost ($) |
ΔC ($) |
Outcome (QALYs) | ΔE (QALYs) | C/E ($/QALY) |
ICER ($/QALY) |
NMB ($) |
|
---|---|---|---|---|---|---|---|
Decision model | |||||||
WTP = $50,000 | |||||||
Non-almond | 1524 | Ref | 0.94 | Ref | 1625 | Dominated | 45,373 |
Almond | 1161 | −363 | 0.96 | 0.02 | 1211 | 46,794 | |
WTP = $100,000 | |||||||
Non-almond | 1524 | Ref | 0.94 | Ref | 1625 | Dominated | 92,270 |
Almond | 1161 | −363 | 0.96 | 0.02 | 1211 | 94,749 | |
WTP = $200,000 | |||||||
Non-almond | 1524 | Ref | 0.94 | Ref | 1625 | Dominated | 186,064 |
Almond | 1161 | −363 | 0.96 | 0.02 | 1211 | 190,658 | |
Sensitivity–Probabilistic Sensitivity Analysis | |||||||
Non-almond | 1555 ± 59 | Ref | 0.94 ± 0.0005 | Ref | 1658 ± 63 | 45,333 ± 84 | |
Almond | 1589 ± 417 | 34 ± 414 | 0.94 ± 0.02 | 0.005 ± 0.02 | 1694 ± 474 | −26,798 ± 814,514 | 45,542 ± 1245 |
Sensitivity–10-year model | |||||||
Non-almond | 20,871 | Ref | 8.13 | Ref | 2566 | Dominated | 385,788 |
Almond | 15,120 | −5750 | 8.37 | 0.24 | 1806 | 403,377 | |
Sensitivity–cost of procedure | |||||||
Non-almond | 1524 | Ref | 0.94 | Ref | 1625 | Dominated | 45,373 |
Almond | 1161 | −363 | 0.96 | 0.02 | 1210 | 46,794 | |
Sensitivity–cost of almond | |||||||
Non-almond | 1524 | Ref | 0.94 | Ref | 1625 | Dominated | 45,373 |
Higher cost of almond | 1474 | −50 | 0.96 | 0.02 | 1537 | 46,480 | |
Sensitivity–CVD patients | |||||||
Non-almond | 1213 | Ref | 0.86 | Ref | 1411 | Dominated | 41,766 |
Almond | 1022 | −190 | 0.86 | 0.0001 | 1189 | 41,962 |
Abbreviations: C/E cost-effectiveness ratio, ICER incremental cost-effectiveness ratio, NMB net monetary benefit, QALY quality-adjusted life years, WTP willingness-to-pay